Romidepsin (FK228, Depsipeptide)

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 157 In stock
USD 477 In stock
USD 697 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Concentration over time for each dose cohort of romidepsin (B).

    Blood, 2018, 131(4):397-407. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Impacts of chromopeptide A and FK228 on G2/M transition regulators. PC3 and LNCaP cells were treated with chromopeptide A or FK228 at indicated concentrations for 24 h, and cells lysates were immunoblotted with the indicated antibodies.

    Acta Pharmacol Sin, 2017, 38(4):551-560. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 M1XzOmNmdGxiVnnhZoltcXS7IFHzd4F6 MoLCNk42NTF3IH7N NYLabnNHPzJiaB?= MY\pcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh NW[1PJI6OjV5OUC5NFc>
U2932  MVzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUjET45JOi53LUG1JI5O MUK3NkBp NFrqXHBqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi M4\qfVI2PzlyOUC3
OCI-LY7 NGjNdnhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGfO[nkzNjVvMUWgcm0> M2Xlc|czKGh? MWTpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh Mk\JNlU4QTB7MEe=
Farage M3HDd2NmdGxiVnnhZoltcXS7IFHzd4F6 MnX5Nk42NTF3IH7N NHfjdWE4OiCq NUTONIF6cW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NGfuXGszPTd7MEmwOy=>
LY7/EBV NUDob2M{S2WubDDWbYFjcWyrdImgRZN{[Xl? MoP6Nk42NTF3IH7N MYm3NkBp MV7pcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh M4e4TVI2PzlyOUC3
U2932/EBV MlLsR4VtdCCYaXHibYxqfHliQYPzZZk> NFvVbY4zNjVvMUWgcm0> M2H3fVczKGh? M1fQVIlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NXn4N2JxOjV5OUC5NFc>
HCT116 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUD3OFZ[PS13MECwJI5O MW[yOEBp NXXZNIJ4TE2VTx?= MWDpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= NXOzU5F2OjV2OUK1NVU>
ACH-2 NWPOXJhOTnWwY4Tpc44hSXO|YYm= NInqU|kyNTlibl2= M2LiOlI1KGh? NGi2S4NqdmS3Y3XzJGhKXi1zIFXuekBmgHC{ZYPzbY9v NUP2c5BFOjVzNEm0Olc>
MCF-10A MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nEOGlEPTB;MD6xO:KyOC5yMTDuUS=> MnrFNlQ6PTR6NU[=
MCF-7 M1qwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTFwMUFCtVAvOjBibl2= NWfBWJZXOjR7NUS4OVY>
SK-BR-3 M4LvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\4dGlEPTB;MT6wNOKyOC5|NTDuUS=> NXPGUlJ6OjR7NUS4OVY>
MDA-MB-231 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvCTWM2OD1yLk[4xtExNjF2IH7N MVWyOFk2PDh3Nh?=
PC3 M4fkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTFwNkZCtVAvOzVibl2= MVmyOFk2PDh3Nh?=
HCT116 M3LGZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\2N3VKSzVyPUGuNFDDuTBwMECgcm0> NV3Z[ndkOjR7NUS4OVY>
HCT116-p21-/- NEniXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTDRYtVUUN3ME2xMlI3yrFyLkO3JI5O NUPQS5BuOjR7NUS4OVY>
S1 NEi0OmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUP3dYtFUUN3ME23MlY4yrFyLkK5JI5O MoDENlQ6PTR6NU[=
SW620 Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moi0TWM2OD1yLkmzxtExNjJ7IH7N MkTTNlQ6PTR6NU[=
LOX-IMVI MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwOEhCtVAvODNibl2= MorYNlQ6PTR6NU[=
UACC-62 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\UdGJKSzVyPUCuOVbDuTBwMU[gcm0> NWHvc3N5OjR7NUS4OVY>
MDA-MB-435 NIWy[WtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2OxUGlEPTB;MD65NOKyOC5yNjDuUS=> MVuyOFk2PDh3Nh?=
SF-295 NHfwbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r2XmlEPTB;MD64POKyOC5zNTDuUS=> NX7ISnNtOjR7NUS4OVY>
A549 NV\JfVZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;KPFdKSzVyPUGuNlbDuTBwMkSgcm0> MXeyOFk2PDh3Nh?=
H460 MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[wV5RKSzVyPUKuOVjDuTBwOECgcm0> M3e0TlI1QTV2OEW2
EKVX NVqwXG06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jD[mlEPTB;MT6zN:KyOC5|NDDuUS=> M4LRfVI1QTV2OEW2
H146 NUPxNVF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4K0eGlEPTB;MD6yNuKyOC5yNzDuUS=> NFLCU3IzPDl3NEi1Oi=>
H526 MmK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfSWZRZUUN3ME2wMlE2yrFyLkCzJI5O MXKyOFk2PDh3Nh?=
HuT-78 NGTCcIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rTeWlEPTB;MT63N:KyOC52NDDuUS=> MWKyOFk2PDh3Nh?=
HA MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkWzNE43OjVvMUDuUS=> NH;hXnY1QCCq NV32d2FqcW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ? NXvPWoNsOjR5N{G1NVA>
MS-275 NVXhZlVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[wMlYzPS1zMH7N M3\vUFQ5KGh? MWLpcoR2[2W|IHGgd4lodmmoaXPhcpRtgSC|dILvcodmeiCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBkdy22cnXheIVlKHerdHigZo9zfGW8b33pZi=> M2WxN|I1PzdzNUGw
CD4 T NFWzbFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PyZ|Q5KGh? NInEVIdGSzVyPUSuOeKyOS5yIH7N NYjBR21TOjR5MkK0OVQ>
CD4 T NUK3eGlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTCWFF{PDhiaB?= MVXDR|UxRTFyN9MxNVI3KG6P NYC4WlVMOjR5MkK0OVQ>
CD4+ T M1;XPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3EPIxGSzVyPUOgcm0> NIHxbVgzPDR7NUGwOS=>
A549 NGXIO2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHFWHAyOOLCk{GwNOKhdk1? MojJNlQwOzZxNEigbC=> NWfoW202cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NILCbHMzPDR6NUe5PS=>
JJN3 NVjqSmJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DkUFI1NzR6IHi= NF7VNYtGSzVyPEJihKlvVTtiNElihKlp NFfuNYQzPDB|MEG1NC=>
OPM-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqyOE81QCCq MV;FR|Uxez1z4pEJcm08KDR64pEJbC=> M1\OO|I1ODNyMUWw
RPMI-8226 MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFruTIozPC92ODDo MnTSSWM2OHN;MT645qCKdk19IES45qCKcA>? Mlz1NlQxOzBzNUC=
U266 NI\JSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mni3NlQwPDhiaB?= NHnPPVlGSzVyc{2xNQKBkW6POzC0PQKBkWh? Mm\3NlQxOzBzNUC=
CA46 NFmzNo5CeG:ydH;zbZMhSXO|YYm= M2jGVlYhcA>? NHzaSWtqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= M1PCc|I{QTZ4MU[0
DG75 NFfhNJBCeG:ydH;zbZMhSXO|YYm= M3O2SFYhcA>? MlLIbY5lfWOnczDuc{BieG:ydH;zbZM> MUKyN|k3PjF4NB?=
Ramos MWTBdI9xfG:|aYOgRZN{[Xl? NV;yPYdDPiCq Mm\hbY5lfWOnczDlfJRmdnOrdnWgZZBweHSxc3nz NEnxRXgzOzl4NkG2OC=>
ST486 M{nYbWFxd3C2b4Ppd{BCe3OjeR?= M4\3WVYhcA>? MV7pcoR2[2W|IHX4eIVve2m4ZTDhdI9xfG:|aYO= NIDmOnUzOzl4NkG2OC=>
HuT78 M1nvR2Fxd3C2b4Ppd{BCe3OjeR?= MlrpNU8yOC9zMECgcm0> NWjKdWR3PDhiaB?= M1S2RYlv\HWlZYOgZZBweHSxc3nzJIF1KDFibl2= MlXaNlM2OzJ5M{K=
DpVp35 NH7lOHNCeG:ydH;zbZMhSXO|YYm= MV[xM|ExNzFyMDDuUS=> NV;Rflg6PDhiaB?= NU\sXmdCcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= NI\UNGgzOzV|MkezNi=>
DpVp50 NFH0[lNCeG:ydH;zbZMhSXO|YYm= NEnhTGgyNzFyL{GwNEBvVQ>? MV20PEBp MVXpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? M4TxVVI{PTN{N{Oy
DpP75  NX7BNZA1SXCxcITvd4l{KEG|c3H5 Mo\aNU8yOC9zMECgcm0> NYjPVWYzPDhiaB?= MnrNbY5lfWOnczDicJVvfCCjcH;weI9{cXN? NYL4ZXU1OjN3M{K3N|I>
SKOV-3 MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofwNgKBmzJybl2= NHH6UXI4OiCq NGq1c4ZFVVOR MmPsdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> MYeyN|AyODN2OB?=
Brca1 WT M3HKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[zXZFvOeLCk{Kwcm0> M1rSN|czKGh? NInn[m9FVVOR MlvudoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> NF\5flczOzBzMEO0PC=>
Brca1 Null NVfmZYZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:zWGc3OeLCk{Kwcm0> NVfzXJZ2PzJiaB?= M3qyWGROW09? NFXB[FZz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? NUDpW2o3OjNyMUCzOFg>
OVCAR-8  NFf2TWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWex5qCUOjCwTR?= MWO3NkBp MVHEUXNQ M1zXepJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv MYeyN|AyODN2OB?=
NCI/ADR-RES NV6zVmsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Xn[lHjiJN{MH7N NXTmSYZNPzJiaB?= MWXEUXNQ MWDy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> MWiyN|AyODN2OB?=
HCT116 M{Tqc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWG1JI5ONTVyIN88US=> M4XX[FI1KGh? NHXLWoxFVVOR NYq0XpNLcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? MUCyNlkzPDl3OB?=
RKO NHLLPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXG1JI5ONTVyIN88US=> MlvMNlQhcA>? NIO1b25FVVOR MWfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> M1KxSlIzQTJ2OUW4
CO115 M1zGVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDsdWZ[PSCwTT21NEDPxE1? NFLT[IszPCCq MmWwSG1UVw>? M3LBeYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MVeyNlkzPDl3OB?=
HFS MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYj6Um41PSCwTR?= M1Hrd|I1NzR6L{eyJIg> NUX6fXRUcW6qaXLpeJMh[2WubDDndo94fGhidHnt[U1l\XCnbnTlcpRtgQ>? Mn3QNlIyODZ{OEK=
LNCaP M4DoNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVP6e2diPSCwTR?= NHvqTYgzPC92OD:3NkBp NXrDNXoycW6qaXLpeJMh[2WubDDndo94fGhidHnt[U1l\XCnbnTlcpRtgQ>? MWOyNlExPjJ6Mh?=
A549 NGXZNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf5do42KG6P M3X1bVI1NzR6L{eyJIg> M1nTUolvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> NF7BPJIzOjFyNkK4Ni=>
697  Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDMd4JKSzVy4pEJQgKBkTJwNdMgcm0> M3[2bFIyPTN6MkG2
697-R MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|Ux6oDLPfMAjVgvPsLibl5CpC=> MVmyNVU{QDJzNh?=
HUT78 NYPQUVQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[2R3ZKSzVyPUGgcm0> NVXtXXpYOjFzOUi1OFU>
THJ-16T NFrhXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnlNUBvVQ>? M3vRZVI1KGh? NVT5b5RicW6qaXLpeJMh[2WubDDndo94fGh? NYiwWGRbOjB6MUC1Olg>
HCT116 MmP6SpVv[3Srb36gRZN{[Xl? Mk\GNlAhdk1? NH\BeZc5KGh? MXTtc4R2dGG2ZYOgeJJidnOlcnnweEBt\X[nbIOg[o9zKGi3bnTy[YR{KG:oIHflcoV{KGmwIHXpeIhmeiCmaYLlZ5Rqd25? MVWyNFc{QTR3NB?=
B104  NX7ifWl2TnWwY4Tpc44hSXO|YYm= NWLIVJNFOiCwTR?= NVnyd4U6OjRxNEivO|IhcA>? MnXHbY5kemWjc3XzJJRp\SC|dYLmZYNmKGW6cILld5Nqd25ib3[gR2QzOMLi NEfjWYwzODZ6NkWwOS=>
HL-60  M{H6[WN6fG:2b4jpZ4l1gSCDc4PhfS=> NGfOZVIyNTVyMDDuUS=> MW[yOEBp MnTwbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NYrLPHNXOjB4MkSxOlM>
HP100 NGK5eHBEgXSxdH;4bYNqfHliQYPzZZk> NWjidYF3OS13MECgcm0> MYWyOEBp MXPpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh M{nRVlIxPjJ2MU[z
HL-60  M1TzPGZ2dmO2aX;uJGF{e2G7 M{PTS|ExKG6P Mn7QOE83NzF4IHi= NWTRNnZ3cW6mdXPld{B1cGViZ3Xu[ZJifGmxbjDv[kBpgWS{b3flckBx\XKxeHnk[UBnem:vIETo NUHIdplvOjB4MkSxOlM>
HP100 M{LyOmZ2dmO2aX;uJGF{e2G7 MVGxNEBvVQ>? MkHyOE83NzF4IHi= MknNbY5lfWOnczD0bIUh\2WwZYLheIlwdiCxZjDofYRzd2enbjDw[ZJwgGmmZTDmdo9uKDSq MXmyNFYzPDF4Mx?=
HL-60  MmjwSpVv[3Srb36gRZN{[Xl? MmraNVAuPTByIH7N MlS5OEBp M2Dj[YRm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= NEXJVVgzODZ{NEG2Ny=>
HP100 Ml\qSpVv[3Srb36gRZN{[Xl? NVy5eXBsOTBvNUCwJI5O NUfEXmlmPCCq M3v6ZoRm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= MV2yNFYzPDF4Mx?=
11z NY\2bY93U2mwYYPlJGF{e2G7 NHe2XGE{NTFyMDDuUS=> MXHy[YR2[2W|IFjERWMh\W68eX3heIlkKGGldHn2bZR6KCiLQ{WwxsA:KDZwNTFCtUAxNjZibn3vcE9NMQ>? M4TCW|IxPjB3MUS0
SKOV-3 NXnZVIR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYm0M|gwOTZibl2= NXH4[FI4PDhiaB?= M13TfIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz M{DYZ|IxPDB2NU[0
OVCAR-3 M1vid2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\vc|QwQC9zNjDuUS=> NWjwZnJ4PDhiaB?= NEDScFdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? Ml3wNlA1ODR3NkS=
HBL-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnHWlEzNTFyIH7N NFjaemwzPCCq M{T1emlEPTB;ND6zJI5O M13COFIxODZ6MEiw
Jeko-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLZNmczNTVyIH7N M33wUFI1KGh? MmTmTWM2OD1zMTDuUS=> MoDKNlAxPjhyOEC=
Granta-519 MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWK1MVQxKG6P NV;PTXRyOjRiaB?= NIjmdlNKSzVyPUW4MlUhdk1? NYSyd3E1OjByNkiwPFA>
L1236 MojkR5l1d3SxeHnjbZR6KEG|c3H5 M3ztdFEhdk1vMUCwJO69VQ>? NGDITmg1QCCq M3q4WGVEPTB;MD6wO{DPxE1? NGrIZXoyQTJ|M{S3NC=>
L428 M2PRdGN6fG:2b4jpZ4l1gSCDc4PhfS=> MV[xJI5ONTFyMDFOwG0> M3n5bVQ5KGh? MUfFR|UxRTBwNEOg{txO Mo\TNVkzOzN2N{C=
KM-H2 NIjO[FVEgXSxdH;4bYNqfHliQYPzZZk> MXexJI5ONTFyMDFOwG0> NXzlT5FqPDhiaB?= MU\FR|UxRTBwNUig{txO M1GxSFE6OjN|NEew
L540Cy NEnESnBEgXSxdH;4bYNqfHliQYPzZZk> NXvqXXdzOSCwTT2xNFAh|ryP NWf6d3cyPDhiaB?= MUDFR|UxRTBwMU[g{txO Ml;CNVkzOzN2N{C=
G401 NEG3OXdHfW6ldHnvckBCe3OjeR?= NXHyd5c1OTBibl2= MVeyOE81QC95MjDo MXfEUXNQ M3ixbYlv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> M3rwS|E6OjJzNUi2
STM91-01 MVTGeY5kfGmxbjDBd5NigQ>? M3v0WFExKG6P M2HOVFI1NzR6L{eyJIg> NGnydodFVVOR Ml\obY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u NIqwZpEyQTJ{MUW4Oi=>
SJSC  MX\GeY5kfGmxbjDBd5NigQ>? NG\PNG0yOCCwTR?= NGr2T3AzPC92OD:3NkBp MkfRSG1UVw>? NXPLb4MzcW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v NGfrOXMyQTJ{MUW4Oi=>
BT16  MkjqSpVv[3Srb36gRZN{[Xl? NGfHUoIyOCCwTR?= MXOyOE81QC95MjDo MkXySG1UVw>? NGjWeoRqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> MVOxPVIzOTV6Nh?=
NCI-H1299 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPibYdRUUN3ME20MlbDuTBwMjDu[{9udA>? NV7mPZJxOTlzN{m4PVA>
NCI-2882 MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXsXlJrUUN3ME2xMlbDuTBwMESgcocwdWx? M1PRXFE6OTd7OEmw
HCC95 NWfWNol2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXLeI1KSzVyPUKuOeKyOC5yNTDu[{9udA>? NITMWlIyQTF5OUi5NC=>
NCI-H23 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnZTWM2OD1{LkpCtVAvOiCwZz;tcC=> NXnMU4trOTlzN{m4PVA>
NCI-H157 Ml;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjWZ4VwUUN3ME2xMlbDuTBwMEKgcocwdWx? NXzZeFgyOTlzN{m4PVA>
NCI-H460 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17ET2lEPTB;Mj6xxtExNjB5IH7nM41t NH3aUVQyQTF5OUi5NC=>
NCI-H1975 NHziUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjyV3VKSzVyPUGuN:KyOC5yNDDu[{9udA>? NGTIbXQyQTF5OUi5NC=>
NCI-H820 NGXBbWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDuTWM2OD1{LkVCtVAvOSCwZz;tcC=> MWqxPVE4QTh7MB?=
NCI-H1650 NHSwVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXJTWM2OD12LkpCtVAvOyCwZz;tcC=> NHfibZcyQTF5OUi5NC=>
DTC1 NFywbnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlf4TWM2OD1yLkWxJI5O MVOxPFU3PjJ2Nh?=
KAO Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\EZoxKSzVyPUCuPVEhdk1? MWOxPFU3PjJ2Nh?=
SU-CCS-1 NWHZT5dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwOEmgcm0> Mk[4NVg2PjZ{NE[=
SYO-1 M1iybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;0XGlEPTB;MD62O{BvVQ>? MWSxPFU3PjJ2Nh?=
FUJI NF71WGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XJb2lEPTB;MT6zNUBvVQ>? M{TiTlE5PTZ4MkS2
SKNMC MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInY[pJKSzVyPUGuNVchdk1? NVW3OGdsOTh3Nk[yOFY>
402-91 MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfHTWM2OD1zLkK2JI5O MXKxPFU3PjJ2Nh?=
1765-92 MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnniTWM2OD1zLke3JI5O NWHlPYxqOTh3Nk[yOFY>
JN-DSRCT-1 M122[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3z4[GlEPTB;MT6yOUBvVQ>? MXKxPFU3PjJ2Nh?=
NMS-2PC NH74N3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f1U2lEPTB;MD64NUBvVQ>? M{DDZ|E5PTZ4MkS2
HL60 MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnuUFFlUUN3ME2xMlg3KG6P MX6xPFU3PjJ2Nh?=
A549 NHfs[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPzTWM2OD1|LkK0JI5O NVrx[Gk1OTh3Nk[yOFY>
SW480 M2H6b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fvW2lEPTB;Mj62PUBvVQ>? Ml;aNVg2PjZ{NE[=
MCF7 MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPycoRMUUN3ME2zMlU2KG6P M3vYV|E5PTZ4MkS2
PC-3 M3G3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJwNUGgcm0> NX6z[YdvOTh3Nk[yOFY>
MMRU NGD1T|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X1SGlEPTB;Mj61O{BvVQ>? M{LoNVE5PTZ4MkS2
Hs68 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLwSZpMUUN3ME2+NVAhdk1? NFzHT28yQDV4NkK0Oi=>
hMSC-001F MmfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRT5zMDDuUS=> M1v6SVE5PTZ4MkS2

... Click to View More Cell Line Experimental Data

In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

Protocol

Kinase Assay:

[1]

+ Expand

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research:

[3]

+ Expand
  • Cell lines: HL60, Jurkat, A549, and MCF-7
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Male scid mice inoculated i.p. with U-937 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~1 mg/kg once or twice a week
  • Administration: Treated i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 540.7
Formula

C24H36N4O6S2

CAS No. 128517-07-7
Storage powder
in solvent
Synonyms FR 901228, NSC 630176

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03703375 Not yet recruiting Lymphoma T-Cell Celgene October 15 2018 Phase 3
NCT03547700 Recruiting Lymphoma T-Cell Peripheral Ryan Wilcox|University of Michigan Cancer Center|Takeda|Big Ten Cancer Research Consortium September 26 2018 Phase 1|Phase 2
NCT03355768 Not yet recruiting Lymphoma T-Cell Peripheral Jennifer Amengual|Columbia University September 2018 Phase 3
NCT03593018 Not yet recruiting Relapsed Angioimmunoblastic T-Cell Lymphoma|Refractory Angioimmunoblastic T-cell Lymphoma The Lymphoma Academic Research Organisation|Celgene September 2018 Phase 3
NCT03161223 Recruiting Lymphoma T-Cell Columbia University|University of Bologna|Samsung Medical Center|Celgene June 1 2018 Phase 1|Phase 2
NCT03432741 Recruiting Breast Adenocarcinoma|Recurrent Breast Carcinoma|Recurrent Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Nodal Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IV Breast Cancer AJCC v6 and v7 Mayo Clinic|National Cancer Institute (NCI) March 27 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products4

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) supplier | purchase Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) manufacturer | order Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID